ddr-2 Antibody

What is DDR2 and why is it important in research?

DDR2 is a 130 kDa type I transmembrane glycoprotein belonging to the discoidin-like domain-containing subfamily of receptor tyrosine kinases. The mature human DDR2 consists of a 378 amino acid extracellular domain (ECD) including the discoidin-like domain, a 22 amino acid transmembrane segment, and a 434 amino acid cytoplasmic domain containing the kinase domain . DDR2 is significant in research because it selectively binds to and is activated by fibrillar collagens, particularly collagens I, III, and X, with collagens II and V serving as less efficacious ligands . The receptor plays crucial roles in cell-matrix interactions, collagen remodeling, and signal transduction pathways implicated in multiple pathological conditions including fibrosis, arthritis, and cancer, making it an important target for both basic and translational research .

What are the primary applications of DDR2 antibodies in research?

DDR2 antibodies are employed across multiple research applications, with the most common being Western blotting, immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA) . In Western blotting, DDR2 antibodies typically detect bands at approximately 130-140 kDa, as demonstrated in studies with HEK293 human embryonic kidney cell lines transfected with human DDR2 . For IHC applications, these antibodies enable visualization of DDR2 expression patterns in tissue sections, particularly in contexts where collagen-DDR2 interactions are being investigated . In cell-based assays, DDR2 antibodies can help track receptor localization, activation states, and interactions with downstream signaling molecules, providing insights into DDR2-mediated cellular responses .

How do DDR2 antibodies differ from DDR1 antibodies?

While both DDR1 and DDR2 belong to the same receptor family, their antibodies target distinct epitopes due to the 53% amino acid sequence identity within the extracellular domain between these receptors . When selecting DDR2 antibodies, researchers should verify specificity, as some products may exhibit cross-reactivity with DDR1 – for example, certain commercially available antibodies show approximately 5% cross-reactivity with recombinant human DDR1 in Western blot applications . This distinction is particularly important in research contexts where both receptors may be expressed, such as in HT1080 human fibrosarcoma cells, which express both DDR1 and DDR2, compared to rheumatoid arthritis synovial fibroblasts (RASF) and human dermal fibroblasts (HDF), which predominantly express DDR2 . For accurate experimental interpretation, validation of antibody specificity through appropriate controls, including knockdown experiments, is strongly recommended .

What cell types and tissues typically express DDR2?

DDR2 is widely expressed across multiple cell types and tissues, with notable expression in fibroblasts, including human dermal fibroblasts (HDF) and rheumatoid arthritis synovial fibroblasts (RASF) . Western blot analyses have demonstrated DDR2 expression in human fibrosarcoma cell lines (HT1080), although these cells also express DDR1, unlike RASF and HDF which predominantly express DDR2 . In the context of disease, DDR2 expression is upregulated in several pathological conditions, including hepatic fibrosis following injury, rheumatoid and osteoarthritis, and smooth muscle cell hyperplasia . When designing experiments to study DDR2, researchers should consider the endogenous expression levels in their cell or tissue model and select appropriate controls, particularly when investigating collagen-induced signaling pathways where both DDR2 and integrins may contribute to the observed cellular responses .

What are the optimal conditions for using DDR2 antibodies in Western blotting?

For optimal Western blotting with DDR2 antibodies, several technical considerations should be addressed. Sample preparation should include appropriate cell lysis buffers containing phosphatase inhibitors (such as Calyculin A) when studying phosphorylated forms of DDR2, as demonstrated in studies with transfected HEK293 cells . For protein separation, a 12-230 kDa separation system is recommended, as DDR2 typically appears at approximately 139 kDa under reducing conditions . When using goat anti-human DDR2 antigen affinity-purified polyclonal antibodies, a working concentration of 2.5 μg/mL followed by HRP-conjugated anti-goat IgG secondary antibody (1:50 dilution) has proven effective . For phosphorylated DDR2 detection, phosphotyrosine-specific antibodies (such as 4G10 or pY100) can be used to assess receptor activation status following collagen stimulation . Researchers should also include appropriate positive controls (collagen-stimulated cells) and negative controls (unstimulated cells or knockdown cells) to validate antibody specificity and sensitivity .

How should collagen stimulation be performed to study DDR2 phosphorylation?

Studying DDR2 phosphorylation through collagen stimulation requires careful experimental design. The typical protocol involves stimulating cells with collagen I at a concentration of 100 μg/ml in serum-free medium . The temporal profile of DDR2 phosphorylation is distinct from other receptor tyrosine kinases, with maximal phosphorylation occurring at approximately 24 hours post-stimulation rather than within minutes . This delayed response should be considered when designing time-course experiments. Phosphorylation can be assessed using phosphotyrosine-specific antibodies (4G10 or pY100) or phospho-specific antibodies targeting particular residues such as the activation loop (Tyr736 and Tyr740/Tyr741) . For quantitative analysis, selective reaction monitoring (SRM) has been employed to measure phosphorylation levels at specific tyrosine residues, with statistical analysis using paired Student's t-tests to determine significance (p<0.01) . When comparing wild-type and mutant DDR2 phosphorylation, appropriate statistical methods such as ANOVA with Dunnett's post-test for multiple comparisons should be implemented .

What controls should be included when studying DDR2 function using antibodies?

Robust experimental design for DDR2 function studies should incorporate multiple controls. For knockdown validation experiments, siRNA targeting DDR2 (siDDR2) should be compared with non-targeting siRNA (siNT) and, where relevant, siRNA targeting related proteins such as β1 integrin (siITGB1) to distinguish between DDR2-dependent and integrin-dependent effects . Western blotting for DDR2, target proteins, and loading controls (such as actin) should verify knockdown efficiency . In functional assays involving collagen stimulation, both positive controls (collagen-treated cells) and negative controls (unstimulated cells) should be included, along with pharmacological inhibitors of DDR2 signaling (such as dasatinib at 100 nM) as additional negative controls . For antibody specificity validation, cells expressing DDR2 should be compared with cells lacking DDR2 expression, and when available, recombinant DDR2 can serve as a positive control . When studying DDR2 kinase activity, kinase-dead mutants (K608M and K608E) provide valuable negative controls to confirm kinase-dependent effects .

How can immunohistochemistry with DDR2 antibodies be optimized for tissue samples?

Optimizing immunohistochemistry (IHC) protocols for DDR2 antibodies requires attention to several parameters. While specific dilution recommendations should be determined empirically for each antibody and tissue type, published protocols suggest starting with antibody concentrations in the range of 2.5-5 μg/mL for goat anti-human DDR2 polyclonal antibodies . Antigen retrieval methods may be necessary, particularly for formalin-fixed, paraffin-embedded tissues, with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) commonly used . For dual staining experiments, where DDR2 localization is assessed alongside markers of collagen deposition or cell-specific markers, careful selection of compatible secondary antibodies is essential to avoid cross-reactivity . Appropriate positive controls (tissues known to express DDR2, such as fibrotic liver or arthritic synovium) and negative controls (antibody diluent without primary antibody or tissues from DDR2 knockout models) should be included to validate staining specificity . For quantitative analysis of DDR2 expression in tissues, digital image analysis tools can be employed with standardized scoring methods to ensure reproducibility and minimize observer bias.

How can DDR2 antibodies be used to study receptor activation mechanisms?

Studying DDR2 activation mechanisms requires sophisticated approaches that often combine multiple antibodies targeting different aspects of receptor function. The discoidin-like domain of DDR2 mediates interactions with collagens I, III, and X, with the receptor selectively recognizing the triple helical structure rather than monomeric or denatured collagen . To investigate this interaction, researchers can employ DDR2 antibodies in conjunction with collagen binding assays, where the extracellular domain of DDR2 exists as a non-covalent dimer in solution, and dimerization significantly enhances collagen binding . For autophosphorylation studies, phospho-specific antibodies targeting key residues in the activation loop (Tyr736 and Tyr740/Tyr741) can monitor temporal changes in phosphorylation status following collagen stimulation . Selective reaction monitoring (SRM) mass spectrometry provides a quantitative approach to measuring site-specific phosphorylation events, with representative transitions available in supplementary resources . For studying downstream signaling, antibodies against phosphorylated SHP-2 (particularly at Tyr62 and Tyr542) can be used to track DDR2-dependent phosphorylation events, as demonstrated in studies with kinase-dead DDR2 mutants (K608M and K608E) .

What approaches can be used to study DDR2 interactions with matrix metalloproteinases (MMPs)?

DDR2 activation by collagen induces upregulation of several matrix metalloproteinases (MMPs), including MMP-1, MMP-2, and MMP-13, as well as DDR2 itself . To investigate these interactions, researchers can employ a multi-faceted approach combining DDR2 antibodies with functional MMP assays. Gelatin zymography offers a sensitive method to detect MMP-2 activation, distinguishing between pro-MMP-2 and active MMP-2 forms in conditioned media from DDR2-expressing cells stimulated with collagen . Collagen film degradation assays provide a functional readout of MMP activity, where cells transfected with siNT, siDDR2, or siITGB1 are evaluated for their ability to degrade collagen substrates, with quantification through digital image analysis (scale bars typically set at 270 μm) . For invasion studies, Transwell collagen invasion assays can assess the role of DDR2 in promoting cell invasiveness, with statistical analysis of combined data from multiple independent experiments (typically n=6) using appropriate tests (such as t-tests) to determine significance levels (p<0.001) . Western blotting for MT1-MMP (MMP-14) in cell lysates complements these functional assays by monitoring expression levels of this key MMP that is regulated by DDR2 signaling .

How can researchers investigate DDR2 mutations using antibodies?

Investigating DDR2 mutations, particularly those identified in lung squamous cell carcinoma (SCC), requires a comprehensive approach combining antibody-based techniques with functional assays. The domain organization of DDR2 includes discoidin, discoidin-like, juxtamembrane, and kinase domains, with mutations distributed across these regions . Colony formation assays in 3D collagen I gels provide a functional readout for DDR2 mutant activity, with statistical analysis using ANOVA and Dunnett's post-test to compare mutant DDR2 data with empty vector controls (significance levels: **p<0.01, *p<0.05) . Western blotting with phosphotyrosine antibodies (pY100) following collagen I stimulation for 24 hours can assess autophosphorylation capacity of mutant receptors, with normalized densitometry measurements (relative to loading controls such as tubulin) to quantify phosphorylation levels . For detailed phosphoproteomic analysis, SRM techniques can measure site-specific phosphorylation in wild-type versus mutant DDR2, with statistical significance determined by paired Student's t-test (***p<0.001, *p<0.05) . When possible, structural analysis integrating antibody epitope mapping with mutation location can provide insights into how specific mutations affect receptor conformation and function.

What techniques can be used to study DDR2-dependent signaling pathways?

Investigating DDR2-dependent signaling pathways requires integration of multiple antibody-based techniques. DDR2 autophosphorylation following collagen binding promotes associations with signaling proteins including Shc and Src . In vitro kinase assays measuring the incorporation of 32P into substrate peptides (such as Axltide) can assess DDR2 kinase activity, with data expressed as fold change relative to control conditions . For analysis of DDR2-SHP-2 signaling, temporal profiling of phosphorylation at specific residues (DDR2 activation loop Tyr736 and Tyr740/Tyr741; SHP-2 Tyr62) using SRM provides quantitative data on signaling dynamics, with statistical analysis using paired Student's t-tests (significance: **p<0.01) . Immunoblotting for phosphorylated SHP-2 (particularly at Tyr542) demonstrates temporal up-regulation upon collagen stimulation, while studies with kinase-dead DDR2 mutants (K608M and K608E) confirm kinase-dependent effects . For inhibitor studies, compounds such as dasatinib (100 nM) can block DDR2-mediated signaling, serving as pharmacological tools to dissect pathway components . RNA interference approaches targeting DDR2 versus β1 integrin help distinguish collagen signaling mediated by these different receptors, informing pathway specificity .

How can non-specific binding of DDR2 antibodies be minimized?

Non-specific binding is a common challenge when working with DDR2 antibodies, particularly in applications like Western blotting and immunohistochemistry. To minimize this issue, researchers should implement several optimization strategies. For Western blotting, blocking solutions containing 5% non-fat dry milk or 3-5% BSA in TBST (Tris-buffered saline with 0.1% Tween-20) are typically effective . Optimizing antibody dilution is critical, with empirical testing recommended for each application; for instance, 2.5 μg/mL of goat anti-human DDR2 antigen affinity-purified polyclonal antibody has been successfully employed in Western blot applications . Including appropriate controls is essential: a positive control (DDR2-expressing cells or tissues), negative control (cells with DDR2 knockdown), and specificity control (pre-incubation of antibody with immunizing peptide) . For immunohistochemistry applications, additional steps including endogenous peroxidase blocking (3% hydrogen peroxide), avidin-biotin blocking (for biotin-based detection systems), and Fc receptor blocking (using serum from the species of the secondary antibody) may be necessary . When cross-reactivity with DDR1 is a concern, validation using cells that express DDR2 but not DDR1 (such as RASF or HDF) compared to cells expressing both receptors (such as HT1080) can confirm signal specificity .

What strategies can resolve detection issues in phospho-DDR2 Western blots?

Detection of phosphorylated DDR2 presents unique challenges due to the temporal nature of DDR2 phosphorylation and potential low signal intensity. To overcome these issues, researchers should consider several technical approaches. First, sample preparation should incorporate phosphatase inhibitors (such as sodium orthovanadate, Calyculin A, or commercial phosphatase inhibitor cocktails) to preserve phosphorylation status . The timing of collagen stimulation is critical, as DDR2 exhibits delayed phosphorylation kinetics compared to other receptor tyrosine kinases, with maximal phosphorylation typically observed around 24 hours post-stimulation . For enhanced sensitivity, signal amplification methods such as enhanced chemiluminescence (ECL) systems or fluorescently-labeled secondary antibodies with infrared detection systems can be employed . When direct phospho-DDR2 antibodies yield insufficient signals, phosphotyrosine antibodies (such as 4G10 or pY100) can be used following immunoprecipitation of DDR2, allowing enrichment of the target protein before phosphorylation detection . Quantitative analysis should incorporate normalization to loading controls (such as tubulin) and densitometry measurements from multiple independent experiments (typically n=3), with appropriate statistical analysis to determine significance of observed changes .

How can researchers validate DDR2 antibody specificity in their experimental system?

Validating DDR2 antibody specificity is essential for generating reliable research data. A comprehensive validation approach should include multiple strategies. RNA interference using siRNA targeting DDR2 (siDDR2) compared to non-targeting controls (siNT) provides a powerful method to confirm antibody specificity, with Western blotting to verify knockdown efficiency . For systems amenable to genetic manipulation, CRISPR-Cas9-mediated knockout of DDR2 creates definitive negative controls. When available, tissues or cells from DDR2 knockout models serve as gold-standard negative controls . Antibody cross-reactivity assessment is important, particularly with DDR1; some commercial antibodies show approximately 5% cross-reactivity with recombinant human DDR1 in Western blots . For new experimental systems, comparative analysis across multiple cell types with known DDR2 expression profiles (such as RASF and HDF that express DDR2 but not DDR1, versus HT1080 that expresses both DDRs) can help establish baseline expectations . Epitope mapping, either through manufacturer's information or experimental approaches using truncated recombinant proteins, provides insights into antibody binding regions and potential cross-reactivity sources .

What are the common pitfalls when using DDR2 antibodies in collagen stimulation experiments?

Collagen stimulation experiments with DDR2 antibodies present several potential pitfalls that researchers should anticipate and address. One major consideration is the temporal profile of DDR2 phosphorylation, which differs markedly from most receptor tyrosine kinases; while many RTKs show rapid phosphorylation within minutes, DDR2 exhibits delayed kinetics with phosphorylation peaking around 24 hours post-stimulation . This extended timeline necessitates longer experimental protocols and appropriate time point selection. Another critical factor is collagen preparation and quality; DDR2 selectively recognizes the triple helical structure of native collagen, with significantly reduced binding to denatured collagen . Therefore, proper collagen handling to maintain triple helical structure is essential, including appropriate pH and temperature control during preparation . The collagen source can also impact results, as demonstrated in studies comparing human and bovine collagen II . When studying DDR2-specific effects, researchers must consider potential contributions from integrin-mediated collagen signaling, necessitating appropriate controls such as β1 integrin-inhibitory antibodies (e.g., 6S6) or parallel experiments with siRNA targeting β1 integrin (siITGB1) . Finally, cell density can affect DDR2 activation kinetics and magnitude, requiring standardization across experimental conditions .

How are DDR2 antibodies used in cancer research?

DDR2 antibodies serve as critical tools in cancer research, particularly in studying lung squamous cell carcinoma (SCC) where DDR2 mutations have been identified . For mutation studies, researchers employ colony formation assays in 3D collagen I gels to assess functional consequences of DDR2 mutations, with statistical analysis using ANOVA and Dunnett's post-test to compare mutant DDR2 data with controls . Western blotting with phosphotyrosine antibodies evaluates autophosphorylation capacity of mutant receptors, with normalized densitometry measurements relative to loading controls . In invasion studies, Transwell collagen invasion assays combined with DDR2 antibody staining help assess the role of DDR2 in promoting cancer cell invasiveness . For mechanistic investigations, DDR2 antibodies are used to study interactions with matrix metalloproteinases (MMPs), particularly MT1-MMP, which contributes to collagen degradation and tumor cell invasion . Immunohistochemistry with DDR2 antibodies enables assessment of receptor expression in tumor tissues, potentially correlating with clinical parameters such as tumor stage, grade, and patient outcomes . When combined with phospho-specific antibodies, these approaches provide insights into DDR2 activation status in tumors, informing potential therapeutic targeting strategies .

What role do DDR2 antibodies play in studying fibrosis and inflammatory conditions?

DDR2 antibodies are instrumental in investigating fibrosis and inflammatory conditions, where DDR2 upregulation has been documented in hepatic fibrosis, rheumatoid arthritis, osteoarthritis, and smooth muscle cell hyperplasia . In fibrosis models, DDR2 antibodies help track receptor expression and activation in response to collagen accumulation, with immunohistochemistry and Western blotting providing complementary data on protein localization and expression levels . For mechanistic studies in rheumatoid arthritis synovial fibroblasts (RASF), DDR2 antibodies facilitate investigation of collagen-induced signaling pathways that activate matrix metalloproteinases, contributing to joint destruction . Functional assays combining DDR2 antibodies with collagen film degradation or invasion assays provide insights into how DDR2 signaling influences fibroblast behavior in disease contexts . When studying inflammation, DDR2 antibody staining can be combined with markers of inflammatory cells to assess potential interactions between DDR2-expressing cells and immune components . For therapeutic development, DDR2 antibodies help evaluate the efficacy of targeted interventions, such as small molecule inhibitors (e.g., dasatinib), in blocking disease-associated DDR2 signaling . Multi-parameter analysis incorporating DDR2 staining with markers of fibrosis progression offers a comprehensive view of DDR2's role in disease pathogenesis .

How can DDR2 antibodies contribute to studies of collagen remodeling in development and disease?

DDR2 antibodies facilitate investigation of collagen remodeling processes critical in both development and disease. DDR2 interaction with collagen I inhibits collagen fibrillogenesis and alters collagen fiber morphology, effects that can be studied using DDR2 antibodies in combination with collagen imaging techniques . In developmental studies, DDR2 antibody staining enables tracking of receptor expression in tissues undergoing active matrix remodeling, providing insights into temporal and spatial regulation of collagen-DDR2 interactions . For disease-related collagen remodeling, such as in fibrosis or tumor invasion, DDR2 antibodies help elucidate the mechanisms through which DDR2 activation by collagen induces upregulation of matrix metalloproteinases (MMP-1, -2, and -13) . Functional assays combining DDR2 antibodies with zymography and collagen degradation assays provide quantitative measures of DDR2-dependent MMP activation and subsequent collagen processing . When studying the interplay between DDR2 and integrins in collagen remodeling, parallel experiments with antibodies targeting both receptor systems help distinguish their respective contributions . Advanced imaging approaches incorporating DDR2 antibodies with second harmonic generation microscopy for collagen visualization offer powerful tools to directly observe DDR2-mediated changes in collagen architecture in tissues .

What insights can DDR2 antibodies provide about receptor crosstalk with other signaling pathways?

DDR2 antibodies enable investigation of complex signaling networks involving receptor crosstalk. Following collagen binding, DDR2 autophosphorylation promotes associations with Shc and Src, interactions that can be studied using co-immunoprecipitation with DDR2 antibodies followed by Western blotting for associated proteins . For DDR2-SHP-2 signaling analysis, antibodies targeting phosphorylated SHP-2 (particularly at Tyr62 and Tyr542) help track DDR2-dependent phosphorylation events, with studies using kinase-dead DDR2 mutants (K608M and K608E) confirming kinase-dependent effects . When investigating interplay between DDR2 and integrin signaling in response to collagen, parallel experiments with antibodies targeting DDR2 and β1 integrin (along with inhibitory approaches such as siRNA knockdown or function-blocking antibodies) help delineate their respective contributions to downstream events . For exploring links between DDR2 and MAP kinase pathways, phospho-specific antibodies targeting ERK1/2, p38, and JNK can be combined with DDR2 modulation approaches to assess pathway connectivity . In the context of MMP regulation, DDR2 antibodies used alongside promoter analysis tools help elucidate transcriptional mechanisms by which DDR2 activation influences MMP expression . Time-course experiments with multiple antibodies targeting different components of interconnected signaling networks provide temporal resolution of pathway activation sequences following DDR2 engagement .